BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting

Reuters03-18 20:02

March 18 (Reuters) - Alumis Inc ALMS.O:

ALUMIS ANNOUNCES LATE-BREAKER ORAL PRESENTATION OF PHASE 3 DATA FOR ENVUDEUCITINIB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

Source text: ID:nGNX65rgTr

Further company coverage: ALMS.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620873253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620873253","market":"fut","top_or_hot":-1,"title":"BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting</title></head><body><p><span>March 18 (Reuters)</span><span> - </span>Alumis Inc <span>ALMS.O</span>:</p><ul><li><p>ALUMIS ANNOUNCES LATE-BREAKER ORAL PRESENTATION OF PHASE 3 DATA FOR ENVUDEUCITINIB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING</p></li></ul><p>Source text: <span>ID:nGNX65rgTr</span></p><p>Further company coverage: <span>ALMS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting</title></head><body><p><span>March 18 (Reuters)</span><span> - </span>Alumis Inc <span>ALMS.O</span>:</p><ul><li><p>ALUMIS ANNOUNCES LATE-BREAKER ORAL PRESENTATION OF PHASE 3 DATA FOR ENVUDEUCITINIB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING</p></li></ul><p>Source text: <span>ID:nGNX65rgTr</span></p><p>Further company coverage: <span>ALMS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUA9PTTYV:1","article_id":"2620873253","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620873253","pubTimestamp":1773835350,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual MeetingMarch 18 (Reuters)","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ALMS":"Alumis Inc."},"translate_title":"简介-Alumis宣布在2026年美国皮肤病学会年会上口头介绍Envudeucitinib治疗中重度斑块型银屑病的3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9},"content_text":"BRIEF-Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual MeetingMarch 18 (Reuters) - Alumis Inc ALMS.O:ALUMIS ANNOUNCES LATE-BREAKER ORAL PRESENTATION OF PHASE 3 DATA FOR ENVUDEUCITINIB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETINGSource text: ID:nGNX65rgTrFurther company coverage: ALMS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620873253","isCrawlerRequest":true}